Title

1

4

12

- 2 Diagnostic accuracy of point-of-care testing (POCT) devices for postpartum haemorrhage: A
- 3 protocol of a systematic review and meta-analysis

5 Author names and affiliations

- 6 Eishin Nakamura^{1,2}, Takahiro Mihara¹, Yuriko Kondo¹, Hisashi Noma³, Sayuri Shimizu¹
- ¹Department of Health Data Science, Yokohama City University Graduate School of Data Science,
- 8 Yokohama, Japan
- ²Center for Maternal, Fetal and Neonatal Medicine, Saitama Medical Center, Saitama Medical
- 10 University, Saitama, Japan
- 11 The Institute of Statistical Mathematics, Tokyo, Japan

13 **Author list**

- 14 1. Eishin Nakamura
- 15 Department of Health Data Science, Yokohama City University Graduate School of Data Science,
- 16 Yokohama, Japan
- 17 Center for Maternal, Fetal and Neonatal Medicine, Saitama Medical Center, Saitama Medical
- 18 University, Saitama, Japan
- 19 2. Takahiro Mihara
- 20 Department of Health Data Science, Yokohama City University Graduate School of Data Science,
- 21 Yokohama, Japan
- 22 3. Yuriko Kondo
- 23 Department of Health Data Science, Yokohama City University Graduate School of Data Science,
- 24 Yokohama, Japan
- 25 4. Hisashi Noma
- The Institute of Statistical Mathematics, Tokyo, Japan
- 5. Sayuri Shimizu
- 28 Department of Health Data Science, Yokohama City University Graduate School of Data Science,
- 29 Yokohama, Japan

30

31

Corresponding author

- 32 Takahiro Mihara
- 33 Department of Health Data Science, Yokohama City University Graduate School of Data Science,
- 34 Yokohama City University
- 35 22-2 Seto, Kanazawa-ku, Yokohama, Kanagawa
- 36 Tel: 81-45-787-2311

E-mail: meta.analysis.r@gmail.com

Keywords: postpartum haemorrhage, point-of-care testing devices, hypofibrinogenaemia

41 42

49

Introduction

- 43 In postpartum haemorrhage (PPH), coagulation factors, mainly fibrinogen, are exhausted early
- 44 during the course of the disease, which can easily lead to disseminated intravascular coagulation
- 45 (DIC) and cause maternal mortality. Although some studies have reported the efficacy of
- 46 point-of-care testing (POCT) devices in detecting hypofibrinogenaemia, little research has been
- 47 conducted on their usefulness in the diagnosis of PPH. We plan to perform a systematic review of
- 48 the diagnostic accuracy of existing POCT devices for the diagnosis of hypofibrinogenaemia in PPH.

Methods and analysis

- 50 We plan to identify studies using POCT devices for PPH and perform a systematic review and
- 51 meta-analysis of their accuracy of diagnosing hypofibrinogenaemia. The results of fibrinogen
- 52 measurements using the conventional Clauss method are used as reference standards. Literature
- 53 searches will be conducted using electronic databases (MEDLINE, Embase, Cochrane Database, and
- Web of Science), and two reviewers will screen independently from the search results. The eligible
- literature will be used to synthesise true positive, false positive, true negative, and false negative
- results for the diagnosis of hypofibrinogenaemia. We will estimate the diagnostic accuracy of POCT
- 57 devices for diagnosing hypofibrinogenaemia in patients with PPH using the Reitsma-type bivariate
- 58 random-effects synthesis model and the hierarchical summary receiver operating characteristic
- 59 curve.

60

64

67

68

69

71

75

Ethics and dissemination

- This systematic review will be conducted through the secondary use of literature extracted from
- 62 electronic databases. There are no ethical issues associated with this research. The final integrated
- results will be submitted to a peer-reviewed journal.

Protocol registration

- 65 The study protocol was registered with University Hospital Medical Information Network Clinical
- 66 Trials (UMIN000048272) and PROSPERO (CRD42023394785).

Strengths and limitations of the study

- Studies on the usefulness of POCT devices in the diagnosis of PPH are limited. Our study
 will perform a systematic review of the diagnostic accuracy of existing POCT devices for
- the diagnosis of hypofibrinogenaemia in PPH.
- The study will estimate the diagnostic accuracy of POCT devices using the Reitsma-type
- 73 bivariate random-effects synthesis model and the hierarchical summary receiver operating
- 74 characteristic curve.

The threshold for diagnosing hypofibrinogenaemia, the definition of PPH, and the POCT
devices used may vary between studies and could be a potential source of heterogeneity.
Since most primary studies are observational, it is expected that many unpublished studies
will exist.

• The applicability of the study results may be limited since this systematic review only pertains to the use of POCT devices in pregnant patients with PPH. The number of studies may be limited since there is a wide variety of POCT devices used in PPH.

INTRODUCTION

Background

88 89

90 Postpartum haemorrhage (PPH) causes massive blood loss during labour and is one of the leading 91 causes of maternal death.(1) PPH often presents with severe coagulopathy complicated by 92 disseminated intravascular coagulation (DIC). The level of fibrinogen in the blood, which is 93 considered the first to fall below the haemostatic threshold is particularly important, and blood 94 fibrinogen levels correlate with the severity of PPH.(2) Early diagnosis of hypofibrinogenaemia and 95 the initiation of transfusion therapy are important for improving maternal outcomes. 96 Conventional fibringen testing using the Clauss method is time-consuming and expensive to be 97 installed in primary medical facilities. In recent years, point-of-care testing (POCT) devices that 98 simply estimate blood coagulation function have been used as an initial treatment for PPH, and there 99 are reports of their usefulness in PPH.(3) Moreover, the POCT device allows for rapid testing at a 100 low cost, and the test results correlate well with fibringen levels in conventional blood tests.(4) 101 Although many reports on the effectiveness of POCT devices in clinical practice have been 102 recognised in the fields of cardiovascular surgery(5) and emergency medicine(6), there are limited 103 reports on their use in PPH. Since PPH has a different mechanism than other haemorrhagic diseases 104 such as trauma or cardiac surgery, the usefulness of POCT in other diseases may not be directly 105 applicable. 106 Early diagnosis of coagulopathy, especially hypofibrinogenaemia, in patients with PPH, and 107 appropriate transfusion therapy may contribute to decreased total blood loss and mortality. Hence, 108 early diagnosis of coagulopathy using POCT devices is important for improving the prognosis of 109 PPH.

Clinical role of the index test

In clinical practice, dry haematology, thromboelastography, and thromboelastometry are commonly

used POCT devices.

110111

114

115

117

122

123

Dry haematology can directly and rapidly measure fibringen by measuring the viscosity of the

magnetic particle motion signal using scattered light and calculating the fibrinogen value from the

absorbance.(7) Therefore, it is reasonable to use it for the diagnosis of PPH, in which fibrinogen

levels are particularly important, among other coagulation factors.

118 Thromboelastography enables the comprehensive evaluation of coagulation and haemostatic

function, including the effect of platelets, using whole blood samples. For TEG6s®, the parameters

that could be measured as actual values are 1. reaction time (R), 2. Kinetics (K), 3. Angle, 4.

maximum amplitude (MA), 5. whole blood clot lysis index at 30 minutes after MA(Ly30), 6.

amplitude 10(A-10) and 7. Functional fibrinogen (FLEV), 8. Activated clotting time (ACT) (8).

TEG6s can simultaneously measure four different reagents: Citrated Kaolin (CK), Citrated Kaolin

with Heparinase (CKH), Citrated Rapid TEG (CRT), Citrated Functional Fibrinogen (CFF), and

Citrated Rapid TEG (CRT).

The measurement principle of thromboelastometry is similar to that of thromboelastography but

requires a large number of reagents and pipetting steps. (9) Thromboelastography and

thromboelastometry often investigate and report parameters that correlate more with fibrinogen

values since direct fibringen measurement is not possible.(10)

Objectives

The Population, Index tests, and Target condition (PIT) framework(11) in this study is shown in

133 Table 1.(12)

Table 1: Population, Index tests, Target condition (PIT) framework

Population	Pregnant patients after 20 weeks gestation and postpartum patients.
Index tests	The following POCT devices are defined as index tests.
	1. Dry haematology
	2. Thromboelastography
	3. Thromboelastometry
Target condition	Hypofibrinogenemia in patients with PPH

POCT, point-of-care testing; PPH, postpartum haemorrhage.

The purpose of this study is to perform a systematic review of the diagnostic accuracy of POCT devices in diagnosing hypofibrinogenaemia in patients with PPH. The population, index test, and target conditions are presented in Table 1. The reference standard for diagnosing hypofibrinogenaemia will be based on fibrinogen levels measured using the conventional Clauss method, and the cut-off value for diagnosing hypofibrinogenaemia will be determined based on the values set in each individual study. Figure 1 shows the clinical flowchart of the included studies.

Significance of this review

As mentioned above, there have been numerous reports on the usefulness of POCT devices in emergency medicine and cardiovascular surgery. However, there are few reports on their use in PPH. Compared to non-pregnant women, pregnant women are characterised by circulatory dynamics and blood coagulability. In pregnant women, the circulating blood volume is increased by up to 50%, all coagulation factor activities except for factor 13 are increased, and the fibrinolytic system is relatively suppressed.(12,13) Since fibrinogen requires the highest concentration of any coagulation factor during haemostasis, high-volume transfusion in the setting of PPH is easily complicated by dilutional coagulopathy.(14,15) In addition, PPH consumes large amounts of coagulation factors to stop bleeding from the placental abruption site, which may result in consumptive coagulopathy.(16) Since fibrinogen is the first to be consumed in these coagulation disorders, DIC progresses more

154

155

156

157

158

159

160161

162

163

164

165

166

167168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

rapidly in PPH than in other haemorrhagic diseases. Therefore, given the unique aspects of pregnancy, it is necessary to investigate the effectiveness of POCT devices separately in patients with PPH. If POCT devices demonstrate high diagnostic accuracy for detecting hypofibrinogenaemia in PPH, they can be used to guide treatment strategies for the early identification of coagulation disorders and appropriate transfusion therapy. **METHODS AND ANALYSIS** This systematic review and meta-analysis follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and the PRISMA-Diagnostic Test Accuracy (DTA) statement.(17,18) The study protocol was registered with University Hospital Medical Information Network Clinical Trials (UMIN000048272) and PROSPERO (CRD42023394785). Eligibility criteria **Participants** Pregnant women and postpartum women after 20 weeks gestation and patients with blood loss >1000 ml will be included. To examine the effectiveness of POCT devices in investigating the parameters of bleeding in pregnant women, studies that only include pregnant women with congenital coagulopathy will be excluded. Setting Studies in which the initial treatment for PPH or follow-up after transfusion was administered with POCT will be included. Pilot studies conducted on healthy pregnant women and postpartum mothers will be excluded. index test Only studies using Dry haematology (e.g. CG02N®), Thromboelastography (e.g. TEG®), or Thromboelastometry (e.g. ROTEM®) as an index test will be included. reference standard Only studies that use the Clauss method for fibrinogen measurement as the reference standard will be included. There are three methods for measuring fibrinogen in blood: the Clauss method, the salt precipitation method, and the immunoassay method. The Clauss method is the most widely used internationally, and studies using salting-out and immunoassay methods are excluded.(19) A low blood fibrinogen level in pregnant women is reported to be a risk for PPH at ≤200 mg/dl and a risk for requiring massive blood transfusions at ≤130-155 mg/dl.(20-22) The definition of hypofibrinogenaemia is inconsistent in the literature with fibrinogen ≤ 150 mg/dl and ≤ 200

mg/dl.(23) We plan to collect the literature regardless of the cut-off value of hypofibrinogenaemia

and integrate the results, and we will conduct a subgroup analysis according to the cut-off value if

there are a sufficient number of studies (i.e., \geq five studies) for each cut-off value.

target condition

190

191

192

195

196

197

198 199

201

202

203

204

205206

207

208

209

210

211

This study will include only PPH patients diagnosed with hypofibrinogenemia.

193 Types of studies

Only studies involving humans will be included, and literature on animals will be excluded. Studies

will include randomised controlled trials (RCTs) and non-RCTs (non-randomised controlled trials,

split time-series analyses, before/after comparisons, cohort studies, and case-control studies).

Non-published studies (e.g. conference abstracts and clinical trial protocols) will also be included.

Information sources and search strategy

200 The literature will be searched using electronic databases such as MEDLINE, Embase, the Cochrane

Database, and Web of Science, and references to the corresponding literature will also be evaluated.

A literature search of these databases will be conducted on 15/06/2023.

The search formula for PubMed is shown below in Table 2.

Table 2: The search strategy for PubMed

Search Number	Query
1	"postpartum hemorrhage"[MeSH Terms] OR (postpartum[tiab] AND hemorrhage[tiab])
	OR (postpartum[tiab] AND haemorrhage[tiab])
2	"point of care testing" [MeSH Terms] OR "Point-Of-Care" [tiab] OR (point*[tiab] AND
	care[tiab] AND test*[tiab])
3	dry[tiab] AND hematology[tiab]
4	"thrombelastography"[MeSH Terms] OR "Thromboelastometry"[tiab]
5	"blood coagulation tests" [MeSH Terms] OR (blood[tiab] AND coagulation[tiab] AND
	test*[tiab])
6	"viscoelasti*"[tiab] AND ("haemostat*"[tiab] OR "hemostatics"[MeSH Terms] OR
	"hemostasis"[MeSH Terms])
7	#2 OR #3 OR #4 OR #5 OR #6 OR #7
8	#1 AND #7

Study selection

Data management and selection process

The list of references obtained from the electronic databases will be scanned using literature management software (EndNote®) to remove duplicate references. The titles and abstracts will be screened by two independent reviewers (EN and YK) to assess the inclusion criteria. For references determined to be eligible by at least one of the two reviewers in the primary screening, we will

212

213

214

215

216217

218

219

220

221222

223

224

225

226

227

228

229

230

231

232

233234

235

236

237

238

239

240

241

242243

244

245

246

proceed to the secondary screening process using the full text. Secondary screening using the full text will be conducted for references that qualify in the primary screening and for those that cannot be determined to be eligible based on the title and abstract. Disagreements regarding the eligibility for the study will be resolved through discussion. Data collection process Two independent reviewers (EN and YK) will extract data from the eligible literature. If there are discrepancies in data extraction between the two parties regarding the extraction of data, they will be resolved through discussion. Data items Maternal age at delivery, weeks of delivery, primiparity, maternal body mass index, method of delivery (vaginal or cesarean), cause of PPH (atonic bleeding, perineal laceration, retained or adhered placenta, placental abruption, amniotic fluid embolism), total blood loss, total blood transfusion requirements (Red Cell Concentrate, Fresh Frozen Plasma, Platelet Concentrate, fibrinogen concentrate), maternal deaths, blood fibrinogen levels measured by the Clauss method at the time of POCT device use, type of POCT device used, measurement results of POCT devices [(1) dry-haematology: fibrinogen, (2) thromboelastography: R, K, MA, Ly30, A-10, FLEV, (3) thromboelastometry: CT, CF, CFT, alpha, A10, MCF, LI30, LI60, ML], and the number of patients in the true positive, false positive, true negative, and false positive will be collected as diagnostic accuracy for hypofibrinogenemia. **Outcomes and prioritization** Primary outcome The primary outcome is the diagnostic accuracy of the POCT device to determine hypofibrinogenemia. Hypofibrinogenemia is diagnosed based on the fibrinogen values measured using the Clauss method. Secondary outcomes The secondary outcome is the correlation coefficient between the fibrinogen value measured using the Clauss method and the test values measured using POCT. Risk of bias in individual studies QUADAS-2 (24) will be used to assess the risk of bias for each study; QUADAS-2 is classified into the following four domains: (1) participant selection, (2) index test, (3) reference standard, and (4) flow and timing. For each domain, the risk of bias is classified as 'low', 'unclear', and 'high', and

concerns about applicability are also classified as 'low', 'unclear', and 'high'. Signalling questions are also included to facilitate the evaluation of the risk of bias for each domain.

Data synthesis and meta-analysis

247

248

249

266

267

268 269

270

272 273

279 280

250 251 Firstly, we will present the predictive accuracy measures of individual studies based on the reported 252 counts of true positives, false positives, false negatives, and true negatives; sensitivities and 253 specificities will be calculated, accompanied by their corresponding 95% confidence intervals. 254 Coupled forest plots will be used to visualize sensitivities and specificities of POCT for diagnosing 255 hypofibrinogenaemia. In addition, scatter plots will be generated for pairs of sensitivities and 256 specificities to perform exploratory evaluations and assess heterogeneity. 257 Secondly, we will perform synthesis analyses using Reitsma's bivariate random-effects model to 258 account for possible heterogeneities across studies based on study-specific sensitivities and 259 specificities.(25) The results will be the summary estimates of sensitivities and specificities, along with their heterogeneity variances (τ^2). Furthermore, we will generate summary receiver operating 260 261 characteristic (SROC) curves(26) based on bivariate random-effects model estimates and report the 262 areas under the curves (AUCs) as a summary measure of diagnostic accuracy.(27,28) For statistical 263 inference, we will employ standard restricted maximum likelihood estimation for Reitsma's 264 model(25) and use the bootstrap method to calculate 95% confidence intervals for the AUCs of the 265 SROC curves.(29) We will also perform a generalised Egger test for multivariate meta-analysis to

Confidence of cumulative evidence

Once sufficient results have been obtained, the Grading of Recommendations, Assessment,

assess potential publication bias.(30) Statistical analyses will be performed using R software (R

Development Core Team, Vienna, Austria) and RStudio (RStudio, Boston, Massachusetts, USA).

271 Development, and Evaluations (GRADE) will be used to evaluate the certainty of evidence.(31)

Subgroup analyses

- 274 If different thresholds for hypofibrinogenaemia are adopted among the eligible studies, subgroup
- 275 analyses will be considered according to the prespecified clinically relevant thresholds (≤150 mg/dl,
- 276 ≤200 mg/dl). In addition, to evaluate possible heterogeneity, subgroup analyses will be performed
- 277 based on the types of POCT devices used (dry haematology, thromboelastography, and
- 278 thromboelastometry).

DISCUSSION

- 281 Early detection of hypofibrinogenaemia in PPH and appropriate coagulation factor replacement are
- 282 crucial to improve the prognosis of PPH. However, no previous systematic review has reported the

usefulness of POCT devices in PPH. This systematic review focuses on the diagnostic accuracy of POCT for hypofibrinogenaemia and may provide data for the effective use of POCT devices in PPH. This study will focus on blood fibrinogen levels in patients with obstetric haemorrhage. Fibrinogen level is the most important coagulation index in the blood of patients with PPH. Although many coagulation factors are necessary for haemostasis, fibrinogen is required in the highest concentration in the blood.(32) When massive haemorrhage occurs due to PPH, high-volume intravenous infusion to maintain blood pressure can easily lead to dilutional coagulopathy. (33) Furthermore, there is a risk of consumptive coagulopathy, in which a large amount of coagulation factors is consumed to stop bleeding from the placental abruption surface. Moreover, fibrinogen is also the first to be consumed.(34) Therefore, it is reasonable to assume that early recognition of hypofibrinogenemia and appropriate blood transfusion therapy will improve the prognosis of PPH compared to other massive haemorrhages. In PPH, early identification of hypofibrinogenaemia and administering fibrinogen concentrate may reduce the total amount of blood transfusion required and improve the prognosis.(23) Early diagnosis of hypofibrinogenaemia using POCT devices and the development of transfusion protocols may improve maternal outcomes in PPH and conserve medical resources, including transfusion products.(35) This systematic review aims to determine the effectiveness of POCT in the diagnosis of hypofibrinogenaemia in patients with PPH. If POCT devices are reliable for accurately diagnosing hypofibrinogenaemia and determining the minimum transfusion volume needed to correct coagulopathy, they could potentially increase maternal survival rates and reduce the burden on medical resources.

Limitations and implications

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304 305

306

307

308

309

310

311

312

313

314

315316

317

318

This systematic review has several limitations. First, the heterogeneity among the studies may be an issue. The threshold for diagnosing hypofibrinogenaemia, the definition of PPH, and the POCT devices used may vary between studies and could be a potential source of heterogeneity. Second, since most primary studies are observational, it is expected that many unpublished studies will exist. Third, the applicability of the study results may be limited since this systematic review only pertains to the use of POCT devices in pregnant patients with PPH. Fourth, the number of studies may be limited since there is a wide variety of POCT devices used in PPH. If there are insufficient reports for each device, the results of all POCT devices may be combined, making it difficult to determine the most effective device since there will be no direct comparison between the devices.

ETHICS AND DISSEMINATION

This systematic review will finally be submitted for publication in a peer-reviewed journal. The data used in this study do not include individual patient data, so there are no patient privacy concerns.

319 There are also no restrictions on the release of data. Any significant changes from this protocol will

320 be described in detail.

321322

324325

332333

335

336

339

342343

Acknowledgements

We would like to thank Editage (www.editage.com) for English-language editing.

Author contributions

- 326 Conceptualization: Ehisin Nakamura, Takahiro Mihara, Sayuri Shimizu
- 327 Methodology: Eishin Nakamura, Takahiro Mihara, Yuriko Kondo, Hisashi Noma
- 328 Supervision: Takahiro Mihara, Sayuri Shimizu, Hisashi Noma
- 329 Writing Original Draft Preparation: Eishin Nakamura
- Writing Review & Editing: Eishin Nakamura, Takahiro Mihara, Yuriko Kondo, Hisashi Noma,
- 331 Sayuri Shimizu.

Competing Interests

334 None declared.

Funding

- 337 This research received no specific grant from any funding agency in the public, commercial or
- 338 not-for-profit sectors.

340 **Word count**

341 3876 words

References:

- 344 1. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic
- analysis. Lancet Glob Health. 2014;2:e323–33.
- 2. Era S, Matsunaga S, Matsumura H, et al. Usefulness of shock indicators for determining
- 347 the need for blood transfusion after massive obstetric hemorrhage. J Obstet Gynaecol Res
- 348 2015;41:39–43.
- 349 3. Collins PW, Cannings-John R, Bruynseels D, et al. Viscoelastometry guided fresh frozen
- 350 plasma infusion for postpartum haemorrhage: OBS2, an observational study. Br J Anaesth
- 351 2017;119:422–34.
- 4. Hayakawa M, Gando S, Ono Y, et al. Rapid evaluation of fibrinogen levels using the
- 353 CG02N whole blood coagulation analyzer. Semin Thromb Hemost 2015;41:267–71.

- 354 5. Bolliger D, Tanaka KA. Point-of-care coagulation testing in cardiac surgery. Semin
- 355 Thromb Hemost 2017;43:386–96.
- 356 6. Da Luz LT, Nascimento B, Shankarakutty AK, et al. Effect of thromboelastography
- 357 (TEG®) and rotational thromboelastometry (ROTEM®) on diagnosis of coagulopathy, transfusion
- guidance and mortality in trauma: descriptive systematic review. Crit Care. 2014;18:1–26.
- 359 7. Ogawa S, Tanaka KA, Nakajima Y, et al. Fibrinogen measurements in plasma and whole
- 360 blood: a performance evaluation study of the dry-hematology system. Anesth Analg.
- 361 2015;120:18–25.
- 362 8. Othman M, Kaur H. Thromboelastography (TEG). Methods Mol Biol 2017;1646:533–43.
- 363 9. Schöchl H, Nienaber U, Hofer G, et al. Goal-directed coagulation management of major
- trauma patients using thromboelastometry (ROTEM®)-guided administration of fibrinogen
- concentrate and prothrombin complex concentrate. Crit Care 2010;14:1–11.
- 366 10. Lloyd-Donald P, Churilov L, Cheong B, et al. Assessing TEG6S reliability between
- devices and across multiple time points: A prospective thromboelastography validation study. Sci
- 368 Rep 2020;10:7045.
- 369 11. Leeflang MM, Davenport C, Bossuyt PM. Chapter 6: Defining the review question. 2022.
- 370 12. Hill CC, Pickinpaugh J. Physiologic changes in pregnancy. Surg Clin North Am
- 371 2008;88:391–401.
- 372 13. Hui C, Lili M, Libin C, et al. Changes in coagulation and hemodynamics during
- pregnancy: a prospective longitudinal study of 58 cases. Arch Gynecol Obstet 2012;285:1231–6.
- 374 14. Zentai C, Van Der Meijden PEJ, Braunschweig T, et al. Hemostatic therapy using
- 375 tranexamic acid and coagulation factor concentrates in a model of traumatic liver injury. Anesth
- 376 Analg 2016;123:38–48.
- 377 15. Levy JH, Szlam F, Tanaka KA, et al. Fibrinogen and hemostasis: a primary hemostatic
- target for the management of acquired bleeding. Anesth Analg. 2012;114:261–74.
- 379 16. Thachil J, Toh CH. Disseminated intravascular coagulation in obstetric disorders and its
- acute haematological management. Blood Rev 2009;23:167–76.
- 381 17. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and
- meta-analyses: the PRISMA statement. PLoS Med. 2009;6:336–41.
- 383 18. McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, Clifford T, et al.
- 384 Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy
- 385 Studies: The PRISMA-DTA Statement. JAMA. 2018 Jan 23;319(4):388–96.
- 386 19. Stang LJ, Mitchell LG. Fibrinogen. Methods in Molecular Biology. 2013;992:181–92.
- 20. Cortet M, Deneux-Tharaux C, Dupont C, Colin C, Rudigoz RC, Bouvier-Colle MH, et al.
- 388 Association between fibrinogen level and severity of postpartum haemorrhage: Secondary analysis
- 389 of a prospective trial. Br J Anaesth. 2012;108(6):984–9.

- 390 21. Charbit B, Mandelbrot L, Samain E, Baron G, Haddaoui B, Keita H, et al. The decrease of
- 391 fibrinogen is an early predictor of the severity of postpartum hemorrhage. Journal of Thrombosis and
- 392 Haemostasis. 2007 Feb 1;5(2):266–73.
- 393 22. Wang L, Matsunaga S, Mikami Y, Takai Y, Terui K, Seki H. Pre-delivery fibrinogen
- 394 predicts adverse maternal or neonatal outcomes in patients with placental abruption. Journal of
- 395 Obstetrics and Gynaecology Research. 2016 Jul 1;42(7):796–802.
- 396 23. Matsunaga S, Takai Y, Seki H. Fibrinogen for the management of critical obstetric
- hemorrhage. J Obstet Gynaecol Res. 2019 Jan 1;45(1):13–21.
- 398 24. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al.
- 399 QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern
- 400 Med. 2011 Oct 18;155(8):529–36.
- 401 25. Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH.
- 402 Bivariate analysis of sensitivity and specificity produces informative summary measures in
- diagnostic reviews. J Clin Epidemiol. 2005;58:982–90.
- 404 26. Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of
- diagnostic test accuracy evaluations. Stat Med 2001;20:2865–84.
- 406 27. Leeflang MMG, Deeks JJ, Gatsonis C, et al. Systematic reviews of diagnostic test
- 407 accuracy. Ann Intern Med 2008;149:889–97.
- 408 28. Macaskill P, Gatsonis C, Deeks J, et al. Cochrane Handbook for Systematic Reviews of
- 409 Diagnostic Test Accuracy.
- 410 29. Noma H, Matsushima Y, Ishii R. Confidence interval for the AUC of SROC curve and
- 411 some related methods using bootstrap for meta-analysis of diagnostic accuracy studies. Commun
- 412 Stat Case Stud Data Anal Appl 2020;7:344–58.
- 413 30. Hong C, Salanti G, Morton SC, et al. Testing small study effects in multivariate
- 414 meta-analysis. Biometrics. 2020;76:1240.
- 415 31. GRADE Working Group. Grading quality of evidence and strength of recommendations.
- 416 BMJ. 2004;328:1490-4.

- 417 32. Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood
- loss with plasma-poor red cell concentrates. Anesth Analg 1995;81:360–5.
- 419 33. Levy JH, Szlam F, Tanaka KA, et al. Fibrinogen and hemostasis: a primary hemostatic
- 420 target for the management of acquired bleeding. Anesth Analg 2012;114:261–74.
- 421 34. Thachil J, Toh CH. Disseminated intravascular coagulation in obstetric disorders and its
- acute haematological management. Blood Rev 2009;23:167–76.
- 423 35. Snegovskikh D, Souza D, Walton Z, et al. Point-of-care viscoelastic testing improves the
- 424 outcome of pregnancies complicated by severe postpartum hemorrhage. J Clin Anesth 2018;44:50–6.

Figure legend:

426

428 429

Figure 1: clinical flowchart of postpartum haemorrhage (PPH) patients

